CURIOSITYSTREAM INC (CURI) Fundamental Analysis & Valuation

NASDAQ:CURI • US23130Q1076

3.175 USD
-0.15 (-4.37%)
Last: Mar 9, 2026, 12:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CURI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to CURI. CURI was compared to 80 industry peers in the Entertainment industry. The financial health of CURI is average, but there are quite some concerns on its profitability. CURI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. CURI Profitability Analysis

1.1 Basic Checks

  • In the past year CURI has reported negative net income.
  • CURI had a positive operating cash flow in the past year.
  • In the past 5 years CURI always reported negative net income.
  • CURI had negative operating cash flow in 4 of the past 5 years.
CURI Yearly Net Income VS EBIT VS OCF VS FCFCURI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

  • CURI has a worse Return On Assets (-7.30%) than 63.75% of its industry peers.
  • With a Return On Equity value of -11.56%, CURI perfoms like the industry average, outperforming 46.25% of the companies in the same industry.
Industry RankSector Rank
ROA -7.3%
ROE -11.56%
ROIC N/A
ROA(3y)-32.15%
ROA(5y)-36.84%
ROE(3y)-44.33%
ROE(5y)-58.97%
ROIC(3y)N/A
ROIC(5y)N/A
CURI Yearly ROA, ROE, ROICCURI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • The Gross Margin of CURI (54.50%) is comparable to the rest of the industry.
  • CURI's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for CURI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.5%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.26%
GM growth 5YN/A
CURI Yearly Profit, Operating, Gross MarginsCURI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. CURI Health Analysis

2.1 Basic Checks

  • CURI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CURI has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, CURI has more shares outstanding
  • There is no outstanding debt for CURI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CURI Yearly Shares OutstandingCURI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CURI Yearly Total Debt VS Total AssetsCURI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • CURI has an Altman-Z score of -1.12. This is a bad value and indicates that CURI is not financially healthy and even has some risk of bankruptcy.
  • CURI's Altman-Z score of -1.12 is on the low side compared to the rest of the industry. CURI is outperformed by 72.50% of its industry peers.
  • CURI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -1.12
ROIC/WACCN/A
WACC10.13%
CURI Yearly LT Debt VS Equity VS FCFCURI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • CURI has a Current Ratio of 1.62. This is a normal value and indicates that CURI is financially healthy and should not expect problems in meeting its short term obligations.
  • CURI has a Current ratio of 1.62. This is in the better half of the industry: CURI outperforms 68.75% of its industry peers.
  • A Quick Ratio of 1.62 indicates that CURI should not have too much problems paying its short term obligations.
  • CURI's Quick ratio of 1.62 is fine compared to the rest of the industry. CURI outperforms 70.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.62
Quick Ratio 1.62
CURI Yearly Current Assets VS Current LiabilitesCURI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. CURI Growth Analysis

3.1 Past

  • CURI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 67.86%, which is quite impressive.
  • CURI shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.62%.
  • Measured over the past years, CURI shows a very negative growth in Revenue. The Revenue has been decreasing by -10.47% on average per year.
EPS 1Y (TTM)67.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)28.62%
Revenue growth 3Y-10.47%
Revenue growth 5YN/A
Sales Q2Q%45.66%

3.2 Future

  • CURI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 50.40% yearly.
  • The Revenue is expected to grow by 13.02% on average over the next years. This is quite good.
EPS Next Y68.12%
EPS Next 2Y44.4%
EPS Next 3Y36.66%
EPS Next 5Y50.4%
Revenue Next Year41.59%
Revenue Next 2Y23.63%
Revenue Next 3Y21.34%
Revenue Next 5Y13.02%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CURI Yearly Revenue VS EstimatesCURI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
CURI Yearly EPS VS EstimatesCURI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1

More info and screens

Find the best growth stocksShow best growing peers

3

4. CURI Valuation Analysis

4.1 Price/Earnings Ratio

  • CURI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • A Price/Forward Earnings ratio of 155.64 indicates a quite expensive valuation of CURI.
  • CURI's Price/Forward Earnings is on the same level as the industry average.
  • CURI's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 24.60.
Industry RankSector Rank
PE N/A
Fwd PE 155.64
CURI Price Earnings VS Forward Price EarningsCURI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150

4.2 Price Multiples

  • 68.75% of the companies in the same industry are more expensive than CURI, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of CURI indicates a rather cheap valuation: CURI is cheaper than 91.25% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 15.37
EV/EBITDA 19.18
CURI Per share dataCURI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • CURI's earnings are expected to grow with 36.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.4%
EPS Next 3Y36.66%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. CURI Dividend Analysis

5.1 Amount

  • CURI has a Yearly Dividend Yield of 9.50%, which is a nice return.
  • The stock price of CURI dropped by -26.55% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
  • CURI's Dividend Yield is rather good when compared to the industry average which is at 7.42. CURI pays more dividend than 96.25% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, CURI pays a better dividend.
Industry RankSector Rank
Dividend Yield 9.5%

5.2 History

  • CURI has paid a dividend for less than 5 years, so there is no long track record yet.
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
CURI Yearly Dividends per shareCURI Yearly Dividends per shareYearly Dividends per share 2024 2025 2026 0.1 0.2 0.3

5.3 Sustainability

  • The earnings of CURI are negative and hence is the payout ratio. CURI will probably not be able to sustain this dividend level.
DP-342.83%
EPS Next 2Y44.4%
EPS Next 3Y36.66%
CURI Yearly Income VS Free CF VS DividendCURI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

More info and screens

Find the best dividend stocksShow peers with best dividend

CURI Fundamentals: All Metrics, Ratios and Statistics

CURIOSITYSTREAM INC

NASDAQ:CURI (3/9/2026, 12:00:34 PM)

3.175

-0.15 (-4.37%)

Chartmill FA Rating
GICS IndustryGroupMedia & Entertainment
GICS IndustryEntertainment
Earnings (Last)11-12
Earnings (Next)03-11
Inst Owners34.74%
Inst Owner Change1.4%
Ins Owners8.18%
Ins Owner Change1.09%
Market Cap185.10M
Revenue(TTM)66.59M
Net Income(TTM)-5.45M
Analysts86
Price Target6.63 (108.82%)
Short Float %5.16%
Short Ratio3.91
Dividend
Industry RankSector Rank
Dividend Yield 9.5%
Yearly Dividend0.07
Dividend Growth(5Y)N/A
DP-342.83%
Div Incr Years1
Div Non Decr Years1
Ex-Date03-06
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)11.44%
Min Revenue beat(2)9.49%
Max Revenue beat(2)13.4%
Revenue beat(4)3
Avg Revenue beat(4)6.66%
Min Revenue beat(4)-0.09%
Max Revenue beat(4)13.4%
Revenue beat(8)3
Avg Revenue beat(8)0.56%
Revenue beat(12)6
Avg Revenue beat(12)-2.28%
Revenue beat(16)8
Avg Revenue beat(16)-1.46%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-140%
EPS NY rev (1m)0%
EPS NY rev (3m)-130.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.05%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 155.64
P/S 2.78
P/FCF 15.37
P/OCF 15.27
P/B 3.92
P/tB 9.69
EV/EBITDA 19.18
EPS(TTM)-0.09
EYN/A
EPS(NY)0.02
Fwd EY0.64%
FCF(TTM)0.21
FCFY6.51%
OCF(TTM)0.21
OCFY6.55%
SpS1.14
BVpS0.81
TBVpS0.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.3%
ROE -11.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.5%
FCFM 18.09%
ROA(3y)-32.15%
ROA(5y)-36.84%
ROE(3y)-44.33%
ROE(5y)-58.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.26%
GM growth 5YN/A
F-Score7
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 0.5%
Cap/Sales 0.12%
Interest Coverage N/A
Cash Conversion 152.89%
Profit Quality N/A
Current Ratio 1.62
Quick Ratio 1.62
Altman-Z -1.12
F-Score7
WACC10.13%
ROIC/WACCN/A
Cap/Depr(3y)0.12%
Cap/Depr(5y)1.04%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y68.12%
EPS Next 2Y44.4%
EPS Next 3Y36.66%
EPS Next 5Y50.4%
Revenue 1Y (TTM)28.62%
Revenue growth 3Y-10.47%
Revenue growth 5YN/A
Sales Q2Q%45.66%
Revenue Next Year41.59%
Revenue Next 2Y23.63%
Revenue Next 3Y21.34%
Revenue Next 5Y13.02%
EBIT growth 1Y43.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year188.9%
EBIT Next 3Y51.92%
EBIT Next 5Y26.01%
FCF growth 1Y153.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y154.1%
OCF growth 3YN/A
OCF growth 5YN/A

CURIOSITYSTREAM INC / CURI FAQ

What is the fundamental rating for CURI stock?

ChartMill assigns a fundamental rating of 4 / 10 to CURI.


What is the valuation status for CURI stock?

ChartMill assigns a valuation rating of 3 / 10 to CURIOSITYSTREAM INC (CURI). This can be considered as Overvalued.


Can you provide the profitability details for CURIOSITYSTREAM INC?

CURIOSITYSTREAM INC (CURI) has a profitability rating of 1 / 10.


How sustainable is the dividend of CURIOSITYSTREAM INC (CURI) stock?

The dividend rating of CURIOSITYSTREAM INC (CURI) is 4 / 10 and the dividend payout ratio is -342.83%.